CELLULAR SIGNALLING INHIBITORS, THEIR FORMULATIONS AND METHODS THEREOF

The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula (I), compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/C...

Full description

Saved in:
Bibliographic Details
Main Authors BISWAS, Goutam, KULKARNI, Ashish, SENGUPTA, Shiladitya, SURYAVANSHI, Hemant, ROY, Monideepa, MUKHERJEE, Anubhab
Format Patent
LanguageEnglish
French
German
Published 19.12.2018
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
STEROIDS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula (I), compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/CSF1R signalling pathway with decreased toxicity. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a CSF-1R inhibitor is combined with one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid. The present disclosure also provides a method for treating cancer, allergy, Systemic lupus erythematosus, nephritis, Chronic Obstructive Pulmonary Disease, and abnormal macrophage functions or any combinations thereof.
Bibliography:Application Number: EP20170710396